Samsung Biologics to Participate in 2026 JP Morgan Healthcare Conference

Officially Invited for Ten Consecutive Years
Presentation to Be Delivered in the Grand Ballroom

Samsung Biologics announced on January 4 that it will participate in the 2026 JP Morgan Healthcare Conference (JPMHC), the world's largest pharmaceutical and biotech investment conference.

Celebrating its 44th edition this year, JPMHC is the largest investment conference in the pharmaceutical and biotech industry, held every January in San Francisco, California. This year's event will take place from January 12 to 15 (local time), with around 1,500 pharmaceutical, biotech, and healthcare companies and more than 8,000 participants expected to attend.

John Rim, CEO of Samsung Biologics, is presenting at the 2025 JP Morgan Healthcare Conference in January last year. Samsung Biologics

Having received an official invitation for ten consecutive years since 2017, Samsung Biologics will deliver a corporate presentation at 3 p.m. on January 13 in the Grand Ballroom of The Westin St. Francis, the main venue. The organizers only extend official invitations and presentation opportunities to about 500 leading companies in the industry, and among these, the Grand Ballroom-being the largest hall-serves as the main stage, reserved for just 25 selected companies.

The order of presentations is determined by the importance of each company within the industry. Samsung Biologics is scheduled to present on the second day of the event alongside major global pharmaceutical companies such as GlaxoSmithKline (GSK), AstraZeneca (AZ), and Eli Lilly.

The presentation will be delivered directly by CEO John Rim. The title of the presentation is "ExellenS," the newly launched contract manufacturing (CMO) brand, which is connected to Samsung Biologics' core value of "4E (Excellence)." John Rim will discuss last year's key achievements, this year's business plans and mid- to long-term vision, as well as the company's competitive edge and the foundation for its robust growth.

As a top-tier global contract development and manufacturing organization (CDMO), Samsung Biologics is accelerating its three-pronged expansion strategy focusing on production capacity, business portfolio, and geographic presence to maintain its manufacturing competitiveness. The company continues to secure future growth engines through initiatives such as the transition to a "pure-play CDMO" via a spin-off from Samsung Bioepis Holdings and the acquisition of the Rockville plant in Maryland, USA. Based on these efforts, Samsung Biologics surpassed a cumulative order volume of $20 billion last year and has continued to achieve steady business growth.

During this year's event, Samsung Biologics plans to focus on actively engaging with investors and potential clients to highlight its differentiated global CDMO competitiveness and strengthen networking for business expansion.